Literature DB >> 30109008

Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors.

Penghui Li1, Wenjin Zhang1, Hong Jiang1, Yongliang Li1, Changzhi Dong1,2, Huixiong Chen1,3, Kun Zhang1,4, Zhiyun Du1.   

Abstract

In this study, a series of benzimidazole-rhodanine conjugates were designed, synthesized and investigated for their topoisomerase II (Topo II) inhibitory and cytotoxic activities. The results from Topo II-mediated pBR322 DNA relaxation and cleavage assays showed that the synthesized compounds might act as Topo II catalytic inhibitors. Certain compounds displayed potent Topo II inhibition at 10 μM. The cytotoxic activities of these compounds against HeLa, A549, Raji, PC-3, MDA-MB-201, and HL-60 cancer cell lines were evaluated. The results indicated that these compounds exhibited strong antiproliferative activity. A good relationship was observed between the Topo II inhibitory potency and the cytotoxicity of these compounds. The structure-activity relationship revealed that the electronic effects, the phenyl group, and the rhodanine moiety were particularly important for the Topo II inhibitory potency and cytotoxicity.

Entities:  

Year:  2018        PMID: 30109008      PMCID: PMC6072309          DOI: 10.1039/c8md00278a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  32 in total

1.  Privileged scaffolds or promiscuous binders: a comparative study on rhodanines and related heterocycles in medicinal chemistry.

Authors:  Thomas Mendgen; Christian Steuer; Christian D Klein
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

2.  Synthesis and bioactivity evaluation of rhodanine derivatives as potential anti-bacterial agents.

Authors:  Ming-Xia Song; Chang-Ji Zheng; Xian-Qing Deng; Qing Wang; Shao-Pu Hou; Ting-Ting Liu; Xiao-Lan Xing; Hu-Ri Piao
Journal:  Eur J Med Chem       Date:  2012-05-31       Impact factor: 6.514

3.  Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2.

Authors:  Michael S Christodoulou; Francesco Calogero; Marcus Baumann; Aída Nelly García-Argáez; Stefano Pieraccini; Maurizio Sironi; Federico Dapiaggi; Raffaella Bucci; Gianluigi Broggini; Silvia Gazzola; Sandra Liekens; Alessandra Silvani; Maija Lahtela-Kakkonen; Nadine Martinet; Alfons Nonell-Canals; Eduardo Santamaría-Navarro; Ian R Baxendale; Lisa Dalla Via; Daniele Passarella
Journal:  Eur J Med Chem       Date:  2015-01-20       Impact factor: 6.514

Review 4.  Type I DNA Topoisomerases.

Authors:  Giovanni Capranico; Jessica Marinello; Giovanni Chillemi
Journal:  J Med Chem       Date:  2017-01-24       Impact factor: 7.446

Review 5.  Classification of scaffold-hopping approaches.

Authors:  Hongmao Sun; Gregory Tawa; Anders Wallqvist
Journal:  Drug Discov Today       Date:  2011-10-26       Impact factor: 7.851

6.  Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity.

Authors:  Jose Antonio Ortega; Laura Riccardi; Elirosa Minniti; Marco Borgogno; Jose M Arencibia; Maria L Greco; Anna Minarini; Claudia Sissi; Marco De Vivo
Journal:  J Med Chem       Date:  2017-11-09       Impact factor: 7.446

7.  Switch in Site of Inhibition: A Strategy for Structure-Based Discovery of Human Topoisomerase IIα Catalytic Inhibitors.

Authors:  Ashish T Baviskar; Suyog M Amrutkar; Neha Trivedi; Vikas Chaudhary; Anmada Nayak; Sankar K Guchhait; Uttam C Banerjee; Prasad V Bharatam; Chanakya N Kundu
Journal:  ACS Med Chem Lett       Date:  2015-02-23       Impact factor: 4.345

8.  Scaffold-Hopping of Aurones: 2-Arylideneimidazo[1,2-a]pyridinones as Topoisomerase IIα-Inhibiting Anticancer Agents.

Authors:  Garima Priyadarshani; Anmada Nayak; Suyog M Amrutkar; Sarita Das; Sankar K Guchhait; Chanakya N Kundu; Uttam C Banerjee
Journal:  ACS Med Chem Lett       Date:  2016-09-20       Impact factor: 4.345

9.  2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents.

Authors:  Mohammad Azizmohammadi; Mehdi Khoobi; Ali Ramazani; Saeed Emami; Abdolhossein Zarrin; Omidreza Firuzi; Ramin Miri; Abbas Shafiee
Journal:  Eur J Med Chem       Date:  2012-11-02       Impact factor: 6.514

10.  4-(1,2-diarylbut-1-en-1-yl)isobutyranilide derivatives as inhibitors of topoisomerase II.

Authors:  Michael S Christodoulou; Mikel Zarate; Francesca Ricci; Giovanna Damia; Stefano Pieraccini; Federico Dapiaggi; Maurizio Sironi; Leonardo Lo Presti; Aída Nelly García-Argáez; Lisa Dalla Via; Daniele Passarella
Journal:  Eur J Med Chem       Date:  2016-04-11       Impact factor: 6.514

View more
  4 in total

1.  Design of DNA Intercalators Based on 4-Carboranyl-1,8-Naphthalimides: Investigation of Their DNA-Binding Ability and Anticancer Activity.

Authors:  Sebastian Rykowski; Dorota Gurda-Woźna; Marta Orlicka-Płocka; Agnieszka Fedoruk-Wyszomirska; Małgorzata Giel-Pietraszuk; Eliza Wyszko; Aleksandra Kowalczyk; Paweł Stączek; Katarzyna Biniek-Antosiak; Wojciech Rypniewski; Agnieszka B Olejniczak
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  Anticancer Profile of Rhodanines: Structure-Activity Relationship (SAR) and Molecular Targets-A Review.

Authors:  Jacek Szczepański; Helena Tuszewska; Nazar Trotsko
Journal:  Molecules       Date:  2022-06-10       Impact factor: 4.927

3.  Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors.

Authors:  Wei Zhou; Wenjin Zhang; Yi Peng; Zhi-Hong Jiang; Lanyue Zhang; Zhiyun Du
Journal:  Molecules       Date:  2020-07-12       Impact factor: 4.411

4.  Synthesis, human topoisomerase IIα inhibitory properties and molecular modeling studies of anti-proliferative curcumin mimics.

Authors:  Nehmedo G Fawzy; Siva S Panda; Walid Fayad; ElSayed M Shalaby; Aladdin M Srour; Adel S Girgis
Journal:  RSC Adv       Date:  2019-10-21       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.